Activities and Molecular Mechanisms of Diterpenes, Diterpenoids, and Their Derivatives in Rheumatoid Arthritis

Muhammad Torequl Islam,1 Cristina Quispe,2 Jesús Herrera-Bravo,3,4 Md. Mizanur Rahaman,1 Rajib Hossain,1 Chandan Sarkar,1 Md Abdur Raihan,1 Md. Mashrur Chowdhury,5 Shaikh Jamal Uddin,6 Jamil A. Shilpi,3 João Marcelo de Castro e Sousa,7 Ana Amélia de Carvalho Melo-Cavalcante,7 Mohammad S. Mubarak,8 Javad Sharifi-Rad,9 and Daniela Calina10

1Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
2Facultad de Ciencias de la Salud, Universidad Arturo Prat, Avda. Arturo Prat 2120, Iquique 1110939, Chile
3Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Santiago, Chile
4Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresourse Nucleus, Universidad de La Frontera, Temuco 4811230, Chile
5Department of Pharmacy, Southern University Bangladesh, Arefin Nagar 4210, Chattogram, Bangladesh
6Pharmacy Discipline, Khulna University, Khulna 9208, Bangladesh
7Postgraduate Program in Pharmaceutical Sciences, Federal University of Piaui, Teresina 64049-550, Brazil
8Department of Chemistry, The University of Jordan, Amman 11942, Jordan
9Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador
10Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania

Correspondence should be addressed to Javad Sharifi-Rad; javad.sharifirad@gmail.com and Daniela Calina; calinadaniela@gmail.com

Received 11 October 2021; Revised 11 December 2021; Accepted 2 February 2022; Published 25 March 2022

Diterpenes and their derivatives have many biological activities, including anti-inflammatory and immunomodulatory effects. To date, several diterpenes, diterpenoids, and their laboratory-derived products have been demonstrated for antiarthritis activities. This study summarizes the literature about diterpenes and their derivatives acting against rheumatoid arthritis (RA) depending on the database reports until 31 August 2021. For this, we have conducted an extensive search in databases such as PubMed, Science Direct, Google Scholar, and Clinicaltrials.gov using specific relevant keywords. The search yielded 2708 published records, among which 48 have been included in this study. The findings offer several potential diterpenes and their derivatives as anti-RA in various test models. Among the diterpenes and their derivatives, andrographolide, triptolide, and tanshinone IIA have been found to exhibit anti-RA activity through diverse pathways. In addition, some important derivatives of triptolide and tanshinone IIA have also been shown to have anti-RA effects. Overall, findings suggest that these substances could reduce arthritis score, downregulate oxidative, proinflammatory, and inflammatory biomarkers, modulate various arthritis pathways, and improve joint destruction and clinical arthritic conditions, signs, symptoms, and physical functions in humans and numerous experimental animals, mainly through cytokine and chemokine as well as several physiological interaction pathways. Taken all together, diterpenes, diterpenoids, and their derivatives may be promising tools for RA management.
1. Introduction

Arthritis is a long-term musculoskeletal illness marked by inflammation of the joints. Rheumatoid arthritis (RA) is one of the most common kinds of arthritis [1]. It is a long-term condition marked by inflammatory synovitis. Joint asymmetry and invasive inflammation are common symptoms of RA, which can lead to joint deformity, dysfunction, and even loss of function. Adults in rich countries have a prevalence of 0.5–1.0%, with 5–50 new cases per 100,000 persons each year. Women and the elderly, on the other hand, are the ones who suffer the most [2]. Although the exact origin of RA is unknown, medicinal therapy is a common and effective treatment option for RA patients.

Treatments for RA include nonsteroidal anti-inflammatory medications (NSAIDs), corticosteroids, disease-modifying antirheumatic medicines (DMARDs), and biological response modifiers [3]. All of these anti-RA drugs, unfortunately, have numerous negative effects. NSAIDs may endanger patients’ lives by increasing the risk of upper gastrointestinal (GI) haemorrhage, liver, and kidney damage [4, 5]. Furthermore, headaches, cognitive impairments, and allergic reactions are common reasons for patients to stop taking NSAIDs, limiting their usage. Infection, hyper-splenism, hypertension, osteoporosis, and fractures are all possible side effects of long-term corticosteroid usage [6, 7]. Vomiting, diarrhea, rashes, low white blood cell (WBC) counts, and impaired liver and renal function are also side effects of DMARDs [8, 9].

Biological therapies with high pharmacological selectivity and fewer side effects provide novel RA treatment alternatives [10]. Regrettably, these are pricey. As a result, many patients may be unable to afford these drugs [11]. As a result, it is critical to seek out treatments that have a positive therapeutic benefit, few side effects, and are affordable. Many ailments are treated according to conventional medical principles. Many major studies on therapeutic items with natural origins have been conducted by modern scientists.

Plants or their derivatives, marine items, and so forth are examples. These natural items have been discovered as a promising treatment option for RA [12]. Aside from that, several conventional pharmaceutical formulae for RA care have been difficult. Two significant features of this method are the use of nutraceuticals and polyherbal approaches [13, 14]. However, when these preparations are used in combination with other drugs, they may cause health problems. As a consequence, researchers devised a novel strategy for extracting active chemicals from some of these things. Terpenes, flavonoids, catechins, quinones, alkaloids, anthocya-nins, and anthoxanthins are just a few of the plant-derived phytochemicals that can alter T cell development, inflammatory signaling pathways, and synoviocyte death. As a result, they can be utilized to treat rheumatoid arthritis [15].

Diterpenes are a diverse group of structurally diverse natural chemicals abundant in nature [16, 17]. These are C20 compounds containing four isoprene (C5H8) units that may be found in both terrestrial and marine settings in plants, fungi, bacteria, and animals [18, 19]. Several diterpenes are potential pharmaceutical candidates due to their exceptional pharmacological effect [20–23]. Some diterpenes are considered to be the defining traits of a genus, making them taxonomically significant [24].

Natural diterpenoid compounds come in a wide range of chemical forms and contain many medicinal and economically relevant molecules. All diterpenoids are made from the same substrate, (E, E, E)-geranylgeranyl diphosphate, which is then cyclized into one of the multiple scaffolds by a diterpene synthase [25]. Secondary metabolites with 20 carbon atoms result from the condensation of four isoprene units.

Diterpenoids are divided into approximately 45 distinct categories, and they are also present in marine animals, where their skeletons are fascinating [26]. Based on their skeletal nucleus, diterpenes are classified as linear, bicyclic, tricyclic, tetracyclic, pentacyclic, or macrocyclic. They are usually found in nature polyoxygenated, with keto and hydroxyl groups that are commonly esterified by tiny aliphatic or aromatic acids [27].

Diterpenoids have a variety of biological functions, including antioxidant [23, 28], anti-inflammatory [29, 30], and immune-modulatory action [31]. Given the significance, the goal of this study is to outline the effects of diterpenes, diterpenoids, and their derivatives on RA based on current understanding.

2. Review Methodology

A search with the keywords “Diterpene AND Rheumatoid arthritis,” “Diterpenoid AND Rheumatoid arthritis,” “Diterpene AND Arthritis,” “Diterpenoid AND Arthritis,” and “Diterpene derivative AND Rheumatoid arthritis,” and “Diterpene derivative AND Arthritis” was conducted in the PubMed, Science Direct, Google Scholar, and Clinicaltrials.gov databases. A total of 2708 records were found. After screening, among them, this study used 48 published records that are related to its aim.

This study includes only the records of having antiarthritic or anti-RA along with anti-inflammatory activities of the diterpenes, diterpenoids, and their derivatives obtained from various sources (e.g., medicinal plants and marine origins) on various test systems (e.g., humans), laboratory animals (e.g., mice, rats, and rabbits), and their derivatives (e.g., cells, tissues or organs).

Most of the diterpenes, diterpenoids, and their derivatives have antioxidant and anti-inflammatory properties, and for this reason, this study does not include them. Reports on crude extracts or fractions without chemical characteristics having antiarthritic or anti-RA effects were also excluded in this study.

This study mainly focuses on the anti-RA activities of diterpenes, diterpenoids, and their derivatives. However, it will also focus on the antiarthritic effects of these substances based on updated database records (till 31 August 2021).

3. Physiopathology in RA: A Brief Overview

Since cytokines are directly involved in RA pathogenesis, they have been intensively explored and examined as potential RA targets. Cytokines can be classified as pro or anti-
inflammatory cytokines according to their antigen response activities. TNF-α, interleukins (ILs) (e.g., IL-1β, IL-6, IL-17, IL-18, and IL-23), interferon-gamma (IFN-γ), and granulocyte-macrophage colony-stimulating factor (GM-CSF) have all been found to limit inflammation in the progression of RA. In the synovium, synovial fluid, serum, and peripheral blood of RA patients, these cytokines were detected in high amounts [32–38].

T cell trafficking and proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and MMPs are reduced when IL-7 is blocked, which lowers joint inflammation [39]. The major cause of IL-23-induced synovial inflammation (ROIs) is the activation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT), tyrosine kinase 2, NF-κB, and retinoic acid receptor-related orphan receptors [40].

Macrophages can produce a variety of cytokines such as TNF-α, IL-1β, IL-6, -7, -15, -18, and -23. In this regard, TNF-α may stimulate fibroblast-like synoviocytes (FLS) and synovial cell proliferation through nuclear factor kappa-B (NF-κB) and extracellular regulated protein kinases (ERK). 1/2-E26 transformation-specific (ETS)-1 regulatory pathways [37]. Consequently, several inflammatory mediators such as IL-6 and matrix metalloproteinases (MMP), MMP-1 and MMP-3, are secreted and increase inflammation [41].

Small molecular metabolites such as PGs, lipoxins (LXs), platelet-activating factor (PAF) and leukotrienes (LTs), nitric oxide (NO), and ROS play important roles in the physiopathology of RA [42]. PG expressions such as PGD2, PGE2, PGF2α, PG12, PGJ2, and TXA2 are aberrant in RA [42]. LXs derived from arachidonic acids, such as LXA4 and LXB4, possess anti-inflammatory properties. LXA4 can reduce memory B cell response in RA patients’ synovial tissues by engaging the lipoxin A4 receptor (ALX)/formyl peptide receptor-2 (FPR-2) and, therefore, reduce inflammation [43, 44]. Circulating platelet activation affects leukocyte activity and contributes to inflammation development in RA patients [45]. TNF-α-regulated pathways are known to control PAF, and TNF-α antagonists decrease platelet activation in active RA [46].

Chemokines have a role in the underlying pathophysiology of RA by attracting leukocytes and influencing angiogenesis. Published research indicated that XCl chemokines and their receptors (such as XCL1 and XCR1) are upregulated in RA patients’ mononuclear cells (MNCs) and FLS, respectively [47, 48]. Numerous inflammatory chemokines are mostly generated in the joints of RA patients by synovial macrophages and FLS, while CX3CL1 is produced by synovial endothelial cells. The chemokines CX and CX3C are linked to the recruitment of T lymphocytes and synovial fibroblasts. Furthermore, CX3CL1 and XCL1 stimulate the migration of monocytes and subchondral mesenchymal progenitor cells into the RA synovium, respectively [49]. CC chemokines including CCL2–5, CCL7, CCL13, CCL14, CCL16, CCL18–21, and CCL-25 are differentially expressed in RA plasma and synovium [50]. An upregulated CC chemokine CCL5 is significantly correlated with swollen joints, erythrocyte sedimentation rate (ESR), and c-reactive protein (CRP) in RA patients [51]. On the other hand, CXC chemokines, such as CXCL1, CXCL2, CXCL5, CXCL8, CXCR1, and CXCR2, are generally involved in neutrophil chemotaxis [52]. The chemokine CXCL10 promotes effector T cells into the joint [53].

The expression of peroxisome proliferator-activated receptor-gamma (PPARγ or PPARγ) in human monocytes/MDMs may be an indication of disease activity and treatment effectiveness in RA. Several studies have shown that key cell types in the joints [54, 55] express PPARγ at both the mRNA and protein levels.

Long noncoding RNAs (lncRNAs) are more than 200 nucleotides in length and are extensively expressed in many organs of the human body. Several researchers have shown that lncRNA could be used to diagnose RA [56, 57].

In RA patients with active synovitis, osteoprotegerin (OPG) expression on macrophage type synovial lining cells and also endothelial cells is low. As a result, addressing OPG expression in RA patients’ inflamed joints may be an essential approach for the treatment of RA in humans [58]. The RANKL/OPG pathway is the connecting factor between bone production and bone resorption in the complicated system of bone remodeling. RANKL promotes the activation and differentiation of preosteoclasts and mature osteoclasts by binding to their receptors (RANK).

Certain hormones, growth factors, and cytokines affect the synthesis of RANKL and OPG by osteoblasts in various ways. Thus, the level of proliferation and activity of osteoclasts are determined by the balance of RANKL and OPG. Bone erosions in RA are caused by osteoclastic bone resorption in synovitis sites, in which RANKL expression is also observed [59].

Currently, available anti-RA agents focus on targeting cytokines, chemokines, and various physiological proteins in humans. Adalimumab is an anti-RA medication that prevents TNF and its receptors from binding, thus lowering cytokines (e.g., MMP-1 and MMP-3)-mediated inflammatory mechanisms and cartilage and bone degradation [41]. On the other hand, (5R)-5-hydroxytriptolide can systematically affect the FLS and, in particular, in the process of immune-related processes at 100 nM concentration through a genome-wide microarray assay in RA patients [60]. IL-1 activates the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), apetala (AP)-1, and NF-B activating pathways, which stimulate MMP production and leukocyte adhesion to RA FLS [61], whereas oridonin (2–10 M for 24–72 h) suppress RA FLS proliferation in RA [62]. In RA FLS, (5R)-5-hydroxytriptolide (50 and 100 nM) reduced proliferation and invasion, as well as cytokine production (MMP-3, IL-1, and -6) [63]. By stimulating the synthesis of MMPs and NF-κB ligand (RANKL) receptors, IL-6 promotes bone resorption and cartilage degradation [64, 65].

NSAIDs work by reducing the enzymatic activity of the cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins (PGs). NSAIDs inhibit COX-2, which limits PG synthesis at sites of inflammation; however, inhibiting COX-1 in other tissues (e.g., platelets and mucosa) results in classic NSAID side effects such as bleeding and GI ulcers [66]. Summarized scheme of the physiopathology of RA is shown in Figure 1.
4. Anti-RA Activities of Diterpenoids: Actions and Molecular Mechanisms

Diterpenoids are the most prominent source of anti-RA agents with potential pharmacological effects.

4.1. Cytokine Targeting Diterpenes and Their Derivatives.

A recent study has been claimed that diterpenes isolated from Caesalpinia minax (Hance) substantially reduced the change in paw swelling perimeter, arthritic score, and increased bodyweight loss in vivo study [67]. Furthermore, the primary components of the extract were 14 cassane derivatives, such as caesalpins A–H, caesalminaxin A–L, and others, which exhibit a promising effect on the expression of mRNA of the cytokines IL-1β and IL-6 and TNF-α generated by macrophage cells. Moreover, some other diterpenoids (rhodojaponin III, rhodojaponin VI, 2-O-methyl-rhodojaponin, and 5′-β-D-glucopyranosyloxyjasmonic acid) in Rhododendron molle fruits at 0.6 mg/kg dose dramatically reduced RA symptoms in CIA rats [68] by strongly preventing aberrant T and B lymphocyte proliferation and substantially decreased levels of the proinflammatory cytokines IL-1β and IL-6 and TNF-α generated by macrophage cells. Moreover, some other diterpenoids (rhodojaponin III, rhodojaponin VI, 2-O-methyl-rhodojaponin, and 5′-β-D-glucopyranosyloxyjasmonic acid) in Rhododendron molle fruits at 0.6 mg/kg dose dramatically reduced RA symptoms in CIA rats [68] by strongly preventing aberrant T and B lymphocyte proliferation and substantially decreased levels of the proinflammatory cytokines IL-1β and IL-6 and TNF-α generated by macrophage cells. Moreover, some other diterpenoids (rhodojaponin III, rhodojaponin VI, 2-O-methyl-rhodojaponin, and 5′-β-D-glucopyranosyloxyjasmonic acid) in Rhododendron molle fruits at 0.6 mg/kg dose dramatically reduced RA symptoms in CIA rats [68] by strongly preventing aberrant T and B lymphocyte proliferation and substantially decreased levels of the proinflammatory cytokines IL-1β and IL-6 and TNF-α generated by macrophage cells. Moreover, some other diterpenoids (rhodojaponin III, rhodojaponin VI, 2-O-methyl-rhodojaponin, and 5′-β-D-glucopyranosyloxyjasmonic acid) in Rhododendron molle fruits at 0.6 mg/kg dose dramatically reduced RA symptoms in CIA rats [68] by strongly preventing aberrant T and B lymphocyte proliferation and substantially decreased levels of the proinflammatory cytokines IL-1β and IL-6 and TNF-α generated by macrophage cells. Moreover, some other diterpenoids (rhodojaponin III, rhodojaponin VI, 2-O-methyl-rhodojaponin, and 5′-β-D-glucopyranosyloxyjasmonic acid) in Rhododendron molle fruits at 0.6 mg/kg dose dramatically reduced RA symptoms in CIA rats [68] by strongly preventing aberrant T and B lymphocyte proliferation and substantially decreased levels of the proinflammatory cytokines IL-1β and IL-6 and TNF-α generated by macrophage cells. Moreover, some other diterpenoids (rhodojaponin III, rhodojaponin VI, 2-O-methyl-rhodojaponin, and 5′-β-D-glucopyranosyloxyjasmonic acid) in Rhododendron molle fruits at 0.6 mg/kg dose dramatically reduced RA symptoms in CIA rats [68] by strongly preventing aberrant T and B lymphocyte proliferation and substantially decreased levels of the proinflammatory cytokines IL-1β and IL-6 and TNF-α generated by macrophage cells. More...
| Diterpenes/derivatives | Concentration/dose test system                                                                 | Results/mechanisms                                                                 |
|------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Sclareol               | 3.125–100/3.125–12.5 μM SW982 human synovial cell lines in vitro                            | ↓ TNF-α, ↓ IL-6, ↓ NF-κB, ↓ p38, ↓ MAPK, ↓ ERK                                     |
|                        | 5–10 mg/kg (i.p., every other day over 21 days) collagen-induced arthritis DBA/1 mice in vivo | ↓ Swelling in paws, ↓ serum anti-CII antibodies, ↓ IL-1β, ↓ IL-6, ↓ TNF-α, ↓ IL-17 |
|                        | 10 μM LPS-stimulated RAW 264.7 cells in vitro                                                  | ↓ Th17, ↓ Th1, ↓ Multinucleated cell, ↓ Actin ring formation, ↓ TRAP, ↓ MMP-9, ↓ K |
| Excavatolide B         | 2.5–5 mg/kg (s.c.) type II collagen-induced arthritis in rats in vivo                          | ↓ RA characteristics, ↑ histopathological features                                |
|                        | 2.5–10 μM bone marrow macrophages (BMM) cells in vitro                                       | ↓ TRAP-positive multinucleated cells                                               |
|                        | 5–30 mg/kg (i.p., every other day for 8 days) C57/BL6 mice in vivo                            | ↓ Cathepsin K, ↓ MMP-2, ↓ MMP-9, ↓ CD11b, ↓ NFATc1, ↓ IL-17A, ↓ CSF                |
|                        | 50 mg/kg/d combined with methotrexate (2 mg/kg/week, i.p. for 35 days)                       | ↓ RANKL, ↓ NF-κB                                                                  |
| Andrographolide        | 2.5–10 μM LPS-stimulated neutrophils in vitro                                                 | ↓ ERK/MAPK osteoclastogenesis                                                     |
|                        | 25 μM LPS-stimulated neutrophils in vitro                                                    | ↓ Methotrexate effect hepatoprotective                                            |
|                        | 25–50 mg/kg (i.p., for 37 days) adjuvant-induced arthritis C57BL/6 mice in vivo               | ↑ Apoptosis, ↓ TRAPs                                                              |
|                        | 50 mg/kg/d combined with methotrexate (2 mg/kg/week, i.p. for 35 days) Hit的新君's                | ↑ Neutrophil infiltration                                                         |
|                        | adjuvant-induced arthritis C57BL/6 mice in vivo                                               | ↓ NETs in the ankle joints                                                       |
|                        |                                                                                              | ↓ Systemic inflammation                                                           |
| Diterpenes/derivatives | Concentration/dose test system | Results/mechanisms | References |
|-----------------------|--------------------------------|--------------------|------------|
| Triptolide            | 0.1 mg/kg (p.o., for 28 days) | type II collagen-induced arthritis in rats in vivo | Delayed onset of arthritis ↓Arthritis incidence ↓Clinical arthritis severity score ↓Histopathological arthritis severity score ↓Cell-mediated immunity ↓Viability, ↓proliferation, ↑apoptosis ↑Caspase-3 ↓PPAR-γ ↓DNA fragmentation ↓MMP-3, MMP-13 ↓IL-1, ↓IL-17 ↓TNF-α ↓Arthritis scores ↓Density of capillaries, small, medium, and large vessels in the synovial membrane tissues of inflammatory joints ↓Matrigel-induced cell adhesion ↓VEGF, ↓VEGFR, ↓Ang-1, ↓Ang-2, ↓Tie2 ↑TNF-α, ↓IL-17, ↓IL-1β, ↓p38, ↓JNK ↑RANKL ↓NF-κB ↓Osteoclastogenesis ↓JAK2, ↓STAT3 ↓TNF-α, ↓IL-1β, ↓IL-6, ↓IL-12 ↑IL-10 ↑TGF-β1 ↓TNF-α ↓JNK ↓Migration ↑Proliferation ↓Apoptosis ↓Immune system activation in rats |

| 1–4 nM/L MDA-MB-23 human breast tumor cells U266 multiple myeloma cells PC-3 prostate tumor cells in vitro | 6.25–200 nM LPS-stimulated U937 cells in vitro | 9.31–18.62 μg/kg (p.o., for 21 days) collagen-induced arthritis rats in vivo | 2.5–40 nM bone marrow macrophages in vitro male C57BL/6 mice in vivo | 10, 30, and 50 nM HFLS-RA cells in vitro |

| Triptolide (TP) loaded with miR-30-3p inhibitor (MSNs@PCM@TP) | 0.05–0.2 mg/kg (p.o., for 14 days) collagen-induced arthritis in rats in vivo | 12.5–50 nM peripheral blood and synovial fluid of RA patients in vitro | 6.25–200 nM RAW264.7 cells in vitro, 0.5–2 mg/kg (i.p.) mice in vivo | 125–500 nM RAW264.7 cells in vitro |

| (5R)-5-Hydroxytriptolide | Murine RAW264.7 cells in vitro | genome-wide microarray assay in RA patients | 100 nM/mL RA FLS cells in vitro |

| Kirenol | 7.5–30 μg/kg (i.p., for 21 days) collagen-induced arthritis DBA/1 mice in vivo | 0.01–10 nM RSF cells in vitro | SW1353 cells synovial fibroblasts chondrocytes in vitro |

**References**

[78], [79], [80], [81], [72], [82], [83], [84], [85], [86], [69], [60], [63], [87]
Table 1: Continued.

| Diterpenes/derivatives                      | Concentration/dose test system                                                                 | Results/mechanisms                                                                 | References |
|---------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------|
| **Ginkgolide B**                            | 10, 20, 40 μM (i.p., for 43 days) collagen II-induced arthritis male DBA/1J mice in vivo       | ↓Arthritis scores, ↓synovial hyperplasia, ↓Cartilage and bone destruction           | [88]       |
|                                             | 5–80 μM LPS-induced FLS cells in vitro                                                      | ↓Viability                                                                         |            |
|                                             | 1, 10, 25, 50 μM LPS-stimulated murine macrophages in vitro                                | ↓Caspe-3, ↓Bax, ↓Bcl-2, ↓MMP, ↓Wnt-5a, ↓JNK, ↓p65                                 |            |
| **11-epi-Sinulariolide acetate**            | 9 mg/kg (s.c., once every 2 days from day 7 to day 28 postimmunization) adjuvant-induced     | ↓RA characteristics                                                                | [89]       |
|                                             | arthritis in Lewis rats in vivo                                                            | ↓Cathepsin K                                                                       |            |
| **Retinoic acid-platinum (II) complex**     | 0.25–12 μM MH7A cells in vitro                                                            | ↑Apoptosis, ↑cell cycle arrest, ↓MEK/NF-xB                                         | [90]       |
| **Leflunomide in combination with methotrexate** | 2 and 5 mg/kg (i.g.) Sprague-Dawley rats in vivo                                               | ↓IL-1β, ↓IL-6, ↓IL-8, ↓MMP-1, ↓MMP-13                                              | [91]       |
| **Oridonin**                                | 2–10 μg/mL, 24–72 h RA HFLS cells in vitro                                                | ↓Bax, ↓caspase-3, ↓IL-1β, ↓GFP-LC3 punctate dots, ↓ATG5, ↓Beclin1                  | [52]       |
| **Tanshinone IIA**                          | 30 mg/kg (i.p., for 30 days) adjuvant-induced arthritis C57BL/6 mice in vivo                  | ↓Cartilage degradation, ↓neutrophils infiltration                                    | [94]       |
| **Phlomisoside F**                          | 1–80 μM RA HFLS cells in vitro                                                            | ↓IL-6, ↓TNF-α, ↓neutrophil NETosis, ↓Cartilage degradation, ↓neutrophils infiltration| [93]       |
| **Phytol**                                  | 5, 10, 20 mg/kg (p.o., for 28 days) adjuvant-induced arthritis Wistar rats in vivo           | Markedly offset the bodyweight loss, ↓paw edema, ↓arthritis scores                  | [92]       |
| **Resiniferatoxin**                         | 10 μL of 0.001–0.003% (injection) evoked pain scores arthritic C57BL6 mice in vivo         | ↓Arthritis                                                                         | [96]       |
| **Xylopic acid nanoformulation**            | 200 μg/mL RAW 264.7 cells in vitro, 5 mg/kg (i.v.) adjuvant-induced arthritis in SD rats in vivo | Anti-inflammatory                                                                  | [97]       |
| **Cryptotanshinone**                        | 6–18 mg/kg (p.o., for 16 days) type II collagen-induced arthritis in Wistar rats in vivo       | ↓NF-κB, ↓IkB-α                                                                     | [71]       |
|                                             | 5–20 μM LPS-induced Raw264.7 macrophages in vitro                                          | ↓NF-κB, ↓IkB-α                                                                     |            |
|                                             | 20–60 mg/kg (p.o., for 6 weeks) adjuvant-induced arthritis in DBA/1 J mice in vivo          | ↓Inflammation and joint destruction, ↓p300, ↓STAT3                                 | [98]       |
tanshinone IIA suppressed IL-6 and TNF-α in collagen-induced arthritis male DBA/1 mice, whereas perplasia and cartilage erosion in a dose-dependent manner proinflammatory cytokines (e.g., IL-6) and synovium hyperplasia in human and bovine cartilage explants and IL-1, IL-17, human syn [80]. It also prevented MMP-13 production by MMP-3 and MMP-13 gene expression in primary human synovial fibroblasts; lncRNAs, long noncoding RNAs; GAS5, growth arrest-specific 5; IκB, nuclear factor of kappa light polypeptide gene enhancer in B cells; WAKMAR 2, wound and keratinocyte migration–associated long noncoding RNA 2; NF-κB; TRAP, tartrate-resistant acid phosphatase; JNK, c-Jun N-terminal kinase; RSF, rheumatoid synovial fibroblasts; RANKL, receptor activator of NF-κB ligand; OPG, osteoprotegerin; IL, interleukin; 5-lipoxygenase (5-LOX), and increased the expression of IL-1α, IL-6, COX-2, and TNF-β in blood and joints of collagen-induced arthritis DA rats treated with 11–45g/kg/day (i.g.) for 28 days and significantly decreased the expression of angiogenic activators such as TNF-α, IL-17, vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), and Ang-1 [81]. Triptolide also lowered the production of TNF-α, IL-1β, and IL-6 in blood and joints of collagen-induced arthritic rats [82].

Similarly, Kirenol, isolated from Herba siegesbeckiae, at 100–200μg/mL inhibited the migration, invasion, and proinflammatory IL-6 secretion in RA-associated synovial fibroblasts [87]. Moreover, it inhibited the production of proinflammatory cytokines (e.g., IL-6) and synovium hyperplasia and cartilage erosion in a dose-dependent manner in collagen-induced arthritis male DBA/1 mice, whereas tanshinone IIA suppressed IL-6 and TNF-α expression and release in neutrophils and produced neutrophil apoptosis in adjuvant-induced arthritis in female C57BL/6 mice [94].

Phlomisside F (5, 10, and 20 mg/kg, p.o., for 28 days) inhibited the expression of TNF-α, IL-1β, IL-6, COX-2, and 5-lipoxygenase (5-LOX), and increased the expression of IL-10 in complete Freund’s adjuvant-induced arthritis male Wistar rats [94]. 11-epi-Sinulariolide acetate (9 mg/kg, s.c., once every 2 days from day 7 to day 28 postimmunization) reduced the expression of cathepsin K, MMP-9, TRAP, and TNF-α in ankle tissues in adjuvant-induced RA in female Lewis rats [89].

Research findings indicated that retinoic acid-Pt (II) complex (2 and 5 mg/kg, i.g.) drastically decreased IL-1β, IL-6, IL-8, MMP-1, and MMP-13 levels in synovial fluid dose-dependently in Sprague-Dawley rats [90]. It also significantly inhibited the expression of iNOS and COX-2 mRNA proteins in RA rats. Furthermore, retinoic acid-platinum (II) complex (0.25–12 μM) reduced TNF-α-induced proliferation in a concentration-dependent manner in MH7A cells.

In collagen II-induced arthritis male DBA/1J mice, ginkgolide B (10, 20, and 40 μM, i.p., for 43 days) decreased the serum levels of IL-1β, IL-6, TNF-α, MMP-3, and MMP-13 and increased the anti-inflammatory cytokine IL-10 [99]. The synovial production of monocyte chemoattractant protein-1 (MCP-1) may be crucial in the recruitment of mononuclear phagocytes during RA inflammation [100]. Xie et al. [99] demonstrated that ginkgolide B significantly decreases the serum levels of chemokine MCP-1 in arthritis animals.

In animal studies, WB2086, a human PAF receptor analogue of napelline, isolated from Aphanamixis polystachya exhibited inhibitory effects on NO production (IC50: 7.5–13 μmol/L) and reduced the expression of iNOS in LPS-induced RAW 264.7 macrophages [102]. It also decreased paw edema and neutrophil infiltration in the A carrageenan-induced paw edema animal model. On the other hand, aphanamines A–C isolated from Aphanipterus polystachya exhibited inhibitory effects on NO production (IC50: 6.71–15.36 μmol/L) and reduced the expression of iNOS in LPS-stimulated RAW 264.7 macrophages [103].

Serralabdanes A–E isolated from the whole plant of Choranthus serratus also showed inhibitory effects on LPS-induced NO production in RAW264.7 cells [104]. Other compounds such as tripterycoside A–C, 11-O-β-d-glucopyranosyl-neotrienophenolide, and wilfordoside A at 10 μM exerted substantial inhibition of IL-1β secretion in LPS-induced rat primary synovial fibroblasts [105]. Similarly, researchers found that secoferruginol isolated from the heartwood of Cryptomeria japonica modulates human DC function in a fashion that favors Th2 cell polarization [106], whereas songorine, a C20 diterpenoid alkaloid and 12-keto analogue of napelline, isolated from Aconitum soongaricum, exhibited anti-inflammatory and antiarthritis activities [107].

Some of the important proteins involved in RA include JAK, p38 mitogen-activated protein kinase (MAPK), extracellular receptor kinase (ERK), JNK, IL-1 receptor-associated kinase (IRAK)-4, MMPs, toll-like receptor 4 (TLR-4), G protein-coupled receptor kinase (GRK)-2, Bruton’s tyrosine kinase (BTK), CD3, CD11a, CD19, CD20, and CD80. JAK is a component of the JAK/STAT signaling

| Diterpenes/derivatives         | Concentration/dose test system | Results/mechanisms | References |
|-------------------------------|-------------------------------|--------------------|------------|
| Carnosic acid 30–60 mg/kg (i.p., 4 weeks) collagen-induced arthritis in C57BL/KsJ-db/db mice | | [99] |
| Carnosic acid in vivo, 10 or 20 μM mouse bone marrow cells in vitro | | |
Evidence-Based Complementary and Alternative Medicine

system, which is constantly active, resulting in increased levels of MMPs and apoptotic chondrocytes in RA synovial joints [108]. Published research showed that excavatolide B (2.5 and 5 mg/kg, s.c.) in adjuvant (AIA) and type II collagen-induced arthritis in rats attenuate the protein expression of CD11b and nuclear factor of activated T cells 1 (NFATc1) in ankle tissues [75]. Giannelli et al. [109] reported that evaluation of synovial fluid concentrations of TIMPs (e.g., TIMP-1 and TIMP-2) is more reliable than that determined in serum when remodeling cartilage ECM proteins, besides MMPs evaluated. These researchers suggested that both TIMPs and MMP inhibitors might be a potential target for novel RA treatments administered directly into the joint area. In this respect, triptolide (10, 30, and 50 nM) in RA FLS from 7 RA patients reduced the TNF-β expression levels in the test systems [112]. Additionally, it has been demonstrated that a JNK-specific inhibitor reduces the migration and invasion of RA FLS.

Research by Zhong and colleagues showed that sclareol exhibits antiosteoarthritic properties in IL-1β-induced rabbit chondrocytes and a rabbit model of osteoarthritis induced by ACLT [110]. Sclareol also inhibited MMP, iNOS, and COX-2 expression and increased TIMP-1 expression and ameliorated cartilage degradation in the test systems. Similarly, 11-epi-sinulariolide acetate significantly inhibited the expression of the proinflammatory proteins iNOS and COX-2 in LPS-stimulated murine macrophages [89]. Moreover, oridonin (2–10 μg/mL for 24–72 h) increased apoptosis, protein levels of Bax, and cleaved caspase-3 in RA FLS. However, it significantly decreased IL-1β levels in the test system [52]. Meanwhile, excavatolide B at 10 μM inhibited multinucleated cell and actin ring formation and also tartrate-resistant acid phosphatase (TRAP or TRAPase), MMP-9, and cathepsin K expression in LPS-stimulated RAW 264.7 cells [75].

Researchers also demonstrated that the soft coral-derived diterpene at 2.5 and 5 mg/kg (s.c.) significantly attenuated the characteristics of RA, improved histopathological features, decreased the number of TRAP-positive multinucleated cells, and attenuated the protein expression of cathepsin K, MMP-2, and MMP-9 in ankle tissues as well as the level of IL-17A and macrophage colony-stimulating factor in adjuvant (AIA) and type II collagen-induced arthritis in rats. Figure 2 shows the possible mechanisms of diterpenes and their derivatives targeting cytokines.

4.2. Chemokines Targeting Diterpenes and Their Derivatives. A clinical trial of E6011 (an anti-CX3CL1 mAb) is currently underway, and it has been shown to have a potential function in active RA patients [111]. In LPS-induced FLS, ginkgolide B (5–80 μM) remarkably inhibited RA FLS viability in a concentration-dependent fashion. It also reduced the apoptotic ratio and enhanced the expression of cleaved caspase-3 and Bax. Furthermore, it reduced Bcl-2 expression in RA FLS, decreased the development of inflammation by regulating inflammatory cytokine secretion and MMP gene expression, and reduced expression levels of Wnt5a, (p)-JNK, and p-P65 in synovial tissues and RA FLS [88].

Other diterpenes, diterpenoids, or their derivatives that inhibit RA FLS include triptolide [79, 83], tanshinone IIA [93], (5R)-5-hydroxytriptolide [60], Kirenol [87], oridonin [52], and triptolide (TP) loaded with miR-30-5p inhibitor [84].

Findings showed that carnosol, carnosic acid, carnosic acid-12-methyl ether, 20-deoxocarnosol, and abeta-8,11,13-triene-11,12,20-triol significantly blunt gene expression levels of iNOS, cytokines/interleukins (IL-1α, IL-6), and chemokines including CCL5/RANTES, CXCL10/IP-10 in murine macrophages (RAW264.7 cells), and human chondrocytes [112].

Figure 3 shows the possible mechanisms of diterpenes and their derivatives targeting chemokines.

4.3. Diterpenes and Their Derivatives Acting on Other Proteins. Triptolide (0.01–10 μM) downregulated PPAR-γ activation and induced DNA fragmentation in RSF in rheumatoid synovial fibroblasts from RA patients [79]. It also decreased arthritis scores and significantly reduced capillaries, small, medium, and large vessel density in the synovial membrane tissues of inflamed joints in bovine type II collagen-induced arthritis DA rats [81]. Moreover, triptolide inhibited Matrigel-induced cell adhesion of HFLS-RA, and HUVEC as well as disrupted tube formation of HUVEC on Matrigel, and suppressed the VEGF-induced chemotactic migration of HFLS-RA and HUVEC, respectively, in arthritis rats. (5R)-5-Hydroxytriptolide increased the rate of osteoprotegerin (OPG) expression in CD3+ T leukomonocytes in peripheral blood and the ratio of OPG/RANKL in both peripheral blood and synovial fluid in peripheral blood and synovial fluid of RA patients [69]. It also inhibited IL-23 secretion in the supernatants of PBMCs and SFMCs in peripheral blood and synovial fluid of RA patients [69]. It additionally prevented collagen-induced arthritis via inhibiting OPG/RANK/RANKL signaling in osteoclastogenesis and IFN-γ signaling in T cells [113, 114]. Recently, Zhou et al. [63] demonstrated that it exerts an anti-RA effect through the WAKMAR2/miR-4478/E2F1/p53 dependent pathway in RA FLS. MEG3 IncRNA overexpression reduces inflammation by affecting the AKT/mTOR signaling pathway [115].

Tanshinone IIA (1–80 μM) exerted cytotoxicity in a concentration-dependent fashion and inhibited the PI3K/AKT signaling pathway in FLS from RA patients [93]. In addition, numerous studies indicated that PGs play an important role in physiological immune responses and in pathological diseases related to inflammation and tissue damage.

In murine macrophages (RAW264.7 cells) and human chondrocytes, carnosol, carnosic acid, carnosic acid-12-methyl ether, 20-deoxocarnosol, and abeta-8,11,13-triene-11,12,20-triol reduced NO and PGE2 production in a concentration-dependent manner. They also significantly reduced iNOS and cytokine (IL-1α and IL-6) gene expression levels in the test systems [112]. Additionally, these substances altered the expression of catabolic and anabolic...
genes in the chondrosarcoma cell line SW1353 and primary human chondrocytes, stimulated by IL-1β, where catabolic genes such as MMP-13 and ADAM metallopeptidase with thrombospondin type 1 motif 4 (ADAMTS-4) that contribute to cartilage erosion were downregulated, whereas anabolic gene expression, particularly Col2A1 and aggregan, was moved towards prepathophysiological equilibrium. Furthermore, carnosol exhibited the greatest overall impact on inflammatory mediators as well as macrophage and chondrocyte gene expression. It significantly inhibited IL-1β-induced nuclear translocation of NF-κB-p65, suggesting that it is primarily regulated through the NF-κB signaling pathway. Lobolide, aembrane diterpene, also acts through the NF-κB signaling pathway [116]. Moreover, androgropholide attenuated mouse cortical chemokine levels from the CC and CXC subfamilies in LPS-induced chemokine upregulation in a mouse model [117].

Table 2 provides the list of diterpenes, diterpenoids, and their derivatives that interact with various proteins involved in inflammatory and RA processes.

4.4. Miscellaneous Pathways in RA Treatment. In type II collagen-induced arthritis in rats, triptolide (0.1 mg/kg, p.o.,
for 28 days) significantly delayed the onset of arthritis. In addition, the arthritis incidence, clinical arthritis severity score, histopathological arthritis severity score, and in vivo cell-mediated immunity to collagen were all reduced [78].

In bovine collagen type II and complete Freund’s adjuvant-induced arthritis in DBA/1 mice, cryptotanshinone (20 and 60 mg/kg, p.o., for 6 weeks) ameliorated the inflammation and joint destruction [98]. It also suppressed p300-mediated STAT3 acetylation in test animals. Similarly, carnosic acid at 30 and 60 mg/kg (i.p., 4 weeks) in collagen-induced arthritis in male C57BL/KsJ-db/db mice and at 10 or 20 μM in mouse bone marrow cells reduced osteoclast formation and bone loss through suppression of inflammation by regulating the ROS-dependent p38 pathway [99]. On the other hand, xylopic acid nanoformulation showed anti-inflammatory and anti-RA effects in RAW 264.7 cells and complete Freund’s adjuvant-induced arthritis in male Sprague-Dawley rats [97].

Research findings showed that 7β-hydroxycalcaratarrin A, a labdane-type diterpenoid derived from Hedychium coronarium, inhibits superoxide anion generation by human neutrophils in response to formyl-L-methionyl-L-leucyl-L-phenylalanine/cytochalasin B (fMLP/CB). It also inhibited fMLP/CB-induced elastase release [118]. Chemotherapy with docetaxel (60 mg/m²) and carboplatin dosed every 3 weeks for 4 cycles to an ovarian carcinoma patient (66-year-old woman) was found to mask RA [119].

Andrographolide (25 μM, for 16 h) in LPS-stimulated neutrophils accelerated apoptosis and inhibited autophagy-dependent extracellular TRAPs formation [77]. It also reduced neutrophil infiltration and NETosis in the ankle joints and relieved the systematic inflammation in adjuvant-induced arthritis C57BL/6 mice. Tanshinone IIA inhibited the NET formation of neutrophils in adjuvant-induced arthritis in female C57BL/6 mice [92]. On the other hand, triptolide (0.01–10 μM) reduced viability and proliferation and induced apoptosis of RSF in a concentration-dependent manner in FLS from RA patients [79]. It also upregulated caspase-3 activity in the test system, whereas retinoic acid-platinum (II) complex (0.25–12 μM) in MH7A cells induced apoptosis and caused the arrest of the cell cycle [90].

Figure 3: Diterpenes and their derivatives targeting chemokines in RA.
in animals, showed hepatoprotective activity, and significantly reduced serum TNF-α, IL-6, and IL-1β levels [76].

Triptolide loaded by a poly-g-glutamic acid-grafted l-phenylalanine ethyl ester copolymer at 6.25–200nM reduced the damaging effects on the liver, kidney, and spleen of mice [85]. In addition, triptolide (100 μg/kg, i.p., 21 days) improved clinical arthritic conditions and joint destruction in collagen-induced arthritis in male DBA/1 mice [83], whereas triptolide-loaded poly(D,L-lactic acid) nanoparticles (0.05–0.2 mg/kg, p.o., for 14 days) in complete Freund's adjuvant-induced arthritis in male Wistar rats significantly inhibited arthritis and exerted a preferable anti-inflammatory effect with long-time administration [86].

In another study, triptolide loaded with miR-30-5p inhibitor significantly inhibited RA synovial fibroblast proliferation and increased apoptosis in collagen-induced arthritis female Sprague-Dawley rats [84]. This nano-preparation also downregulated immune system activation in rats.

Phytol (acyclic diterpene alcohol derived from chlorophyll) at 200 μL (injection in the tail, for 10 days) was found to restore the oxidative-burst effect and induce a strikingly similar IFN-β-dependent pathway in DA rats [95].

Researchers suggested that it may be effective against naturally occurring genetic polymorphisms in the Ncf-1 gene that modulated the activity of the NADPH oxidase complex, which is potentially regulated in the severity of arthritis, whereas 11-epi-sinulariolide acetate significantly inhibited RA characteristics in adjuvant-induced arthritis in female Lewis rats [89].

Resiniferatoxin (10 μL of 0.001 or 0.003%, injection) significantly improved arthritis with monoarticular inflammatory arthritis in evoked pain scores in arthritic male C57BL6 mice [96]. Similarly, tanshinone IIA (30mg/kg, i.p., for 30 days) alleviated cartilage erosion and neutrophil infiltration in the ankle joints and reduced proinflammatory cytokine expression levels in sera in adjuvant-induced arthritis in female C57BL/6 mice [92]. In the complete Freund's adjuvant-induced arthritis rat model, phlomisoside F (5, 10, and 20 mg/kg, p.o., for 28 days) markedly offset the body weight loss, inhibited the paw edema, and reduced the arthritis scores and indices of the thymus and spleen [92]. Leflunomide (20mg once daily) in combination with methotrexate improved signs, symptoms, and physical function in RA patients [91], while ginkgolide B (10, 20, and 40 μM, i.p., for 43 days) in collagen II-induced arthritis male

Table 2: Diterpenes and their derivatives targeting other proteins in rheumatoid arthritis.

| Target proteins | Diterpenes/diterpenoids or their derivatives | Reference |
|-----------------|--------------------------------------------|-----------|
| IL-23           | (5R)-5-Hydroxytriptolide                   | [69]      |
| p38 MAPK        | Sclareol                                   | [74]      |
| ERK             | Triptolide                                 | [70, 74, 81] |
| NF-κB           | Lobolide, andrographolide, scolareol, (5R)-5-hydroxytriptolide, retinoic acid-platinum (II) complex | [60, 70, 74, 90, 112, 116] |
| TRAP            | 11-epi-Sinulariolide acetate, (5R)-5-hydroxytriptolide, excavatolide B, andrographolide | [69, 75, 89, 115] |
| MMPs            | Triptolide, 11-epi-sinulariolide acetate, excavatolide B, ginkgolide B, retinoic acid-platinum (II) complex | [75, 80, 88–90] |
| Cathepsin K     | 11-epi-Sinulariolide acetate, excavatolide B | [75, 89] |
| CD11b           | Excavatolide B                            | [75]      |
| PPAR-γ          | Triptolide                                 | [79]      |
| VEGF, VEGFR, Ang-1, Ang-2, Tie2 | Triptolide                                      | [81]      |
| JNK             | Triptolide, ginkgolide B                   | [81, 83, 88] |
| RANK/RANKL, OPG | Triptolide, andrographolide, (5R)-5-hydroxytriptolide | [69, 70, 72, 113, 114] |
| p-IκB           | (5R)-5-Hydroxytriptolide                   | [69]      |
| TREM-1          | Triptolide                                 | [82]      |
| JAK2            | Triptolide                                 | [82]      |
| STAT3           | Triptolide, cryptotanshinone               | [82, 98]  |
| iNOS            | Sclareol, 11-epi-sinulariolide acetate, carnosol, carnosic acid, carnosic acid-12-methylether, 20-deoxocarnosol and abia-8,11,13-triene-11,12,20-triol, and retinoic acid-platinum (II) complex, aphamines A-C | [89, 90, 102, 103, 110, 112] |
| COX-2           | Sclareol, 11-epi-sinulariolide acetate, retinoic acid-platinum (II) complex | [89, 90, 102, 110] |
| PI3K/AKT        | Tanshinone IIA                             | [93]      |
| 5-LOX           | Phlomisoside F                             | [92]      |
| WAKMAR2/miR-4478/ E2F1/p53 | (5R)-5-Hydroxytriptolide                   | [63]      |
| ADAMTS-4        | Triptolide, carnosol, carnosic acid, carnosic acid-12-methylether, 20-deoxocarnosol, abia-8,11,13-triene-11,12,20-triol | [80, 112] |
| PGE2            | Car nosol, carnosic acid, carnosic acid-12-methylether, 20-deoxocarnosol, abia-8,11,13-triene-11,12,20-triol | [112] |
Figure 4: Continued.
Figure 4: Continued.
DBA/1J mice significantly decreased arthritis scores, synovial hyperplasia, and cartilage and bone destruction [88].

The chemical structures of some anti-RA diterpenes and their derivatives are shown in Figure 4.

5. Discussion

Diterpenes and their derivatives are gaining popularity due to their intriguing biological and pharmacological properties. Thus far, hundreds of natural diterpene compounds from terrestrial and marine species have been described. Many of these compounds have become clinically effective. Plants are an important source of diterpenes. Diterpenes can be linear, bicyclic, tricyclic, tetracyclic, pentacyclic, or macrocyclic. They are typically found in nature in a poly-oxygenated form with keto and hydroxyl groups, which are frequently esterified by small-sized aliphatic or aromatic acids. For example, the anticancer drug taxol is used as a promising anticancer agent for ovarian, breast, and lung cancers. In addition, many of its synthetic derivatives are also examples of medicinal agents in the management of various diseases in humans. Docetaxel, sold under the brand name Taxotere®, is a taxoid antineoplastic drug used to treat a variety of malignancies, including locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer. Moreover, carboplatin, when combined with this drug, was found to mask RA in an ovarian carcinoma patient [119]. Similarly, ginkgolides are other promising diterpenes that have strong and specific antagonistic action against platelet-activating factors rising in shock, burns, ulceration, and inflammatory skin disorders [120]. Additionally, ginkgolide B exhibits multiedge-like anti-RA effects in in vitro and in vivo test models [88]. Meanwhile, the anti-RA diterpene resinsiferatoxin (an ultrapotent vanilloid derived from the latex of Euphorbia resinafera) is promising for bladder hyperreflexia and diabetic neuropathy [120]. In short, diterpenes, diterpenoids, and their derivatives might be promising tools to manage RA and its consequences.

According to current knowledge [50], the most promising therapeutic targets in RA include the following:

1. Cytokines: TNF, IL-1, IL-1R, IL-6A, IL-6R, IL-2, IL-10, IL-15, IL-17, IL-17R, IL-18, and IFN-γ
2. Chemokines: CCL2, CCR9, CX3CL1, CCR1, CCR2, CCR5, CCR7, CXCL10, CXCL12, CXCL13, CXCL16, CXCR1/2, CXCR3, CXCR4, and CXCR7
3. Other related proteins: BTK, CD3, CD11a, CD19, CD20, CD80, GRK2, GM-CSF, IL-23, IRAK-4, JAK, MEK, MMP-9, p38 MAPK, and TLR-4
4. Small molecular metabolites: PGD2, PGE2, PGI2, PGJ2, PGF2α, TXA2, LTB4R, CysLT1R, ALX, PAFR, ROS, iNOS, CB2, and FAAH

This review suggests that diterpenes and their derivatives act on the cytokines (IL-1, IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-17, IL-17A, IL-21, IFN-γ, TNF-α, TGF-β1, MMP5 (e.g., MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13), and MCP-1), chemokines (CCL5 and CXCL10), and many proteins (IL-23, p38 MAPK, ERK, NF-κB, TRAP, cathepsin K, CD11b, PPAR-γ, VEGF, VEGFR, Ang-1, Ang-2, Tie2, JNK, RANK/RANKL, OPG, p-IxB, TREM-1, JAK2, STAT3, iNOS, COX-2, PI3K/AKT, lncRNA GAS5, 5-LOX, WAKMAR2/miR-4478/E2F1/p53, ADAMTS-4, and PGE2).

It appears that diterpenes and their derivatives have multiedge-like actions on different RA models. These compounds exerted anti-RA effects through the cytokine, chemokine, inflammatory/noninflammatory proteins, and small molecular metabolites pathways. Among the diterpenes, triptolide and its derivative (5R)-5-hydroxytriptolide have been found to display promising anti-RA activity in various test systems.

Other hopeful anti-RA diterpenes and diterpenoids found in this updated review include carnosol and carnosic acid and their derivatives, excavatolide B, Kirenol,
ginkgolide B, 11-epi-sinuliolide acetate, oridonin, phlo-
mosiside F, phytol, retinoic acid, resiniferatoxin, sclareol, and xylopic acid among others.

A novel triptolide derivative (also known as LLDT-8), which exhibited anti-RA therapeutic properties, is currently in phase II clinical studies in China [63]. Diterpenes and their derivatives act through multidimensional pathways in different RA animal models. Moreover, triptolide-loaded nanocomplexes also improved anti-RA potential in experimental modalities. Besides these compounds/formulations, androgrophiolide, tanshinone IIA, and its derived compound cryptotanshinone also displayed promising anti-RA effects in test systems.

6. Conclusion
To date, many natural products that have the anti-RA ca-
pacity, including those obtained from medicinal plants and
marine organisms, have been identified. The sources of
diterpenes and diterpenoids are widely distributed. Natural
products, including medicinal plant-derived chemicals, are a
prominent source of semisynthetic and synthetic derivatives.
Hence, nature and modern medicinal science are capable of
providing new and more effective diterpene derivatives.
Diterpenes and their derivatives have been shown to possess
promising immunomodulatory properties in various ex-
perimental models; therefore, these natural bioactive com-
pounds are a promising adjuvant pharmacotherapy in RA.

Data Availability
The data used to support the findings of this study are
available from the corresponding author upon request and
are cited within the article as references.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
All authors made a significant contribution to the work
reported, whether that is in the conception, study design,
execution, acquisition of data, analysis, and interpretation,
or in all these areas, that is, revising or critically reviewing
the article, giving final approval of the version to be pub-
lished, agreeing on the journal to which the article has been
submitted, and confirming to be accountable for all aspects
of the work.

References
[1] K. Almutairi, J. Nossent, D. Preen, H. Keen, and C.
Inderjeeth, “The global prevalence of rheumatoid arthritis:
a meta-analysis based on a systematic review,” Rheumatology
International, vol. 41, no. 5, pp. 863–877, 2021.
[2] P. Miossec, “Rheumatoid arthritis: still a chronic disease,”
Lancet, vol. 381, no. 9870, pp. 884–886, 2013.
[3] M. I. Koenders and W. B. van den Berg, “Novel therapeutic
targets in rheumatoid arthritis,” Trends in Pharmacological
Sciences, vol. 36, no. 4, pp. 189–195, 2015.
[4] R. A. Simon and J. Namazy, “Adverse reactions to aspirin
and nonsteroidal antiinflammatory drugs (NSAIDs),”
Clinical Reviews in Allergy & Immunology, vol. 24, no. 3,
pp. 239–252, 2003.
[5] J.-R. Laporte, L. Ibáñez, X. Vidal, L. Verdrell, and R.
Leone, “Upper gastrointestinal bleeding associated with the use
of NSAIDs: newer versus older agents,” Drug Safety, vol. 27,
no. 6, pp. 411–420, 2004.
[6] A. Ruysen-Witbrand, B. Fautrel, A. Saraux, X. Le-Loët, and
T. Fham, “Infections induced by low-dose corticosteroids in
rheumatoid arthritis: a systematic literature review,” Joint
Bone Spine, vol. 77, no. 3, pp. 246–251, 2010.
[7] D. Satyanarayanasetty, K. Pawar, P. Nadig, and A. Haran,
“Multiple adverse effects of systemic corticosteroids: a case
report,” Journal of Clinical and Diagnostic Research, vol. 9,
no. 5, p. FD01, 2015.
[8] S. T. Gilani, D. A. Khan, F. A. Khan, and M. Ahmed,
“Adverse effects of low dose methotrexate in rheumatoid
arthritis patients,” Journal of the College of Physicians and
Surgeons-Pakistan, vol. 22, no. 2, pp. 101–104, 2012.
[9] E. M. Ruderman, “Overview of safety of non-biologic and
diagnostic DMARDs,” Rheumatology, vol. 51, no. suppl 6,
pp. vi37–vi43, 2012.
[10] G. Murdaca, F. Spanò, and F. Puppo, “Use of leflunomide
plus TNF-α inhibitors in rheumatoid arthritis,” Expert
Opinion on Drug Safety, vol. 12, no. 6, pp. 801–804, 2013.
[11] I. Lekander, F. Borgström, J. Lysholm et al., “The cost-effe-
tiveness of TNF-inhibitors for the treatment of rheu-
matoid arthritis in Swedish clinical practice,” The European
Journal of Health Economics, vol. 14, no. 6, pp. 863–873, 2013.
[12] X. Xia, B. H. May, A. L. Zhang et al., “Chinese herbal
medicines for rheumatoid arthritis: text-mining the classical
literature for potentially effective natural products,” Evi-
dence-Based Complementary and Alternative Medicine,
vol. 2020, Article ID 7531967, 14 pages, 2020.
[13] C. Gioia, B. Lucchino, M. G. Tarsitano, C. Iannuccelli, and
M. Di Franco, “Dietary habits and nutrition in rheumatoid
arthritis: can diet influence disease development and clinical
manifestations?” Nutrients, vol. 12, no. 5, p. 1456, 2020.
[14] L. S. Aswathy, S. Krishnan, J. Peter, V. Sabu, and A. Helen,
“Scientific validation of anti-arthritis effect of Kashayams—a
polyherbal formulation in collagen induced arthritic rats,”
Journal of Ayurveda and Integrative Medicine, vol. 12, no. 1,
pp. 20–27, 2021.
[15] X. Wang, G. Fang, Y. Yang, and Y. Pang, “The newly dis-
covered natural compounds against rheumatoid arthri-
tis—an overview,” Phytochemistry Letters, vol. 34, pp. 50–58,
2019.
[16] M. gaysinski, A. ortalo-Magné, O. P. Thomas, and
G. Culioli, “Extraction, purification, and NMR analysis of
terpenes from brown algae,” in Marine Algae, pp. 207–223,
Humana Press, New York, NY, USA, 2015.
[17] R. A. Khan, R. Hossain, A. Sirajatpanah et al., “Diterpenes/
diterpenoids and their derivatives as potential bioactive leads
against dengue virus: a computational and network phar-
macology study,” Molecules, vol. 26, no. 22, p. 6821, 2021.
[18] L.-G. Lin, C. Ung, Z.-L. Feng, L. Huang, and H. Hu,
“Naturally occurring diterpenoid dimers: source, biosyn-
thesis, chemistry and bioactivities,” Planta Medica, vol. 82,
no. 15, pp. 1309–1328, 2016.
[19] J. R. Hanson, “Diterpenoids of terrestrial origin,” Natural
Product Reports, vol. 34, no. 10, pp. 1233–1243, 2017.
[20] M. T. Islam, “Diterpenes and their derivatives as potential anticancer agents,” *Phytotherapy Research*, vol. 31, no. 5, pp. 691–712, 2017.

[21] M. F. C. J. Paz, M. T. Islam, S. Tabrez et al., “Effect of diterpenes on hepatic system,” *Current Pharmaceutical Design*, vol. 24, no. 35, pp. 4093–4100, 2018.

[22] M. T. Islam, S. K. Bardaweel, M. S. Mubarak et al., “Immunomodulatory effects of diterpenes and their derivatives through NLRP3 inflammasome pathway: a review,” *Frontiers in Immunology*, vol. 11, Article ID 572136, 2020.

[23] R. Hassain, M. T. Islam, P. Ray et al., “Amentoflavone, new hope against SARS-CoV-2: an outlook through its scientific records and an in silico study,” *Pharmacognosy Research*, vol. 13, 2021.

[24] J. De-Paula, L. Bueno, D. Cavalcanti, Y. Yoneshigue-Valentim, and V. Teixeira, “Diterpenes from the brown alga Dictyota crenulata,” *Molecules*, vol. 13, no. 6, pp. 1253–1262, 2008.

[25] M. J. Smanksi, R. M. Peterson, and B. Shen, “Platensimycin and platencin biosynthesis in Streptomyces platensis, showcasing discovery and characterization of novel bacterial diterpene syntheses,” in *Natural Product Biosynthesis by Microorganisms and Plants*, Part A, vol. 515, pp. 163–186, Academic Press, Cambridge, MA, USA, 2012.

[26] L. P. Sandjo and V. Kuate, “Diterpenoids from the medicinal plants of Africa,” in *Medicinal Plant Research in Africa*, Academic Press, Cambridge, MA, USA, pp. 105–133, Elsevier, Amsterdam, Netherlands, 2013.

[27] A. Ludwiczuk, K. Skalicka-Woźniak, and M. I. Georgiev, “Terpenoids,” *Pharmacognosy, Academic Press, Cambridge, MA, USA*, pp. 233–266, 2017.

[28] C. Sy, O. Dangles, P. Borel, and C. Caris-Veyrat, “Interactions between carotenoids from marine bacteria and other micronutrients: impact on stability and antioxidant activity,” *Marine Drugs*, vol. 13, no. 11, pp. 7020–7039, 2015.

[29] X. Huang, B. Lv, S. Zhang, Q. Dai, B.-B. Chen, and L.-N. Meng, “Effects of radix curcumae-derived diterpenoid C on *Helicobacter pylori*-induced inflammation and nuclear factor kappa B signal pathways,” *World Journal of Gastroenterology*, vol. 19, no. 31, pp. 5085–5093, 2013.

[30] L. Gan, Y. Zheng, L. Deng et al., “Diterpenoid lactones with anti-inflammatory effects from the aerial parts of Andrographis paniculata,” *Molecules*, vol. 24, no. 15, pp. 2726, 2019.

[31] X. Lu, L. Li, C.-Y. Zhang, H. Schluesener, and Z.-Y. Zhang, “Natural diterpenoid oridonin ameliorates experimental autoimmune neuritis by promoting anti-inflammatory macrophages through blocking notch pathway,” *Frontiers in Neuroscience*, vol. 13, p. 272, 2019.

[32] C. A. Dinarello, “Historical insights into cytokines,” *European Journal of Immunology*, vol. 37, no. S1, pp. S34–S45, 2007.

[33] V. Goeb, P. Aegerter, R. Parmar et al., “Progression to rheumatoid arthritis in early inflammatory arthritis is associated with low IL-7 serum levels,” *Annals of the Rheumatic Diseases*, vol. 72, no. 6, pp. 1032–1036, 2013.

[34] Y. Guo, N. Wang, S. Zhao, L. Hou, Y. Xu, and N. Zhang, “Increased interleukin-23 is associated with increased disease activity in patients with rheumatoid arthritis,” *Chinese Medical Journal*, vol. 126, no. 5, pp. 850–854, 2013.

[35] N. J. Gullick, H. S. Abozaid, D. M. Jayaraj et al., “Enhanced and persistent levels of interleukin (IL)-17 CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis,” *Clinical & Experimental Immunology*, vol. 174, no. 2, pp. 292–301, 2013.

[36] H. Radner and D. Aletaha, “Anti-TNF in rheumatoid arthritis: an overview,” *Wiener Medizinische Wochenschrift*, vol. 165, no. 1, pp. 3–9, 2015.

[37] A. D. Cook, C. Louis, M. J. Robinson, R. Saleh, M. A. Sleeman, and J. A. Hamilton, “Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation,” *Arthritis Research & Therapy*, vol. 18, no. 1, pp. 207, 2015.

[38] I. V. Reyes-Pérez, P. E. Sánchez-Hernández, J. F. Muñoz-Vallée et al., “Cytokines (IL-15, IL-21, and IFN-γ) in rheumatoid arthritis association with positivity to autoantibodies (RF, anti-CCP, anti-MCV, and anti-PAD14) and clinical activity,” *Clinical Rheumatology*, vol. 38, no. 11, pp. 3061–3071, 2019.

[39] S. A. Y. Hartgring, C. R. Willis, D. Alcorn et al., “Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators,” *Arthritis & Rheumatism*, vol. 62, no. 9, pp. 2716–2725, 2010.

[40] K. A. Knoop, N. Kumar, B. R. Butler et al., “RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium,” *The Journal of Immunology*, vol. 183, no. 9, pp. 5738–5747, 2009.

[41] P. J. Mease, “Adalimumab in the treatment of arthritis,” *Therapeutics and Clinical Risk Management*, vol. 3, p. 133, 2007.

[42] Q. Cheng, H. Wu, and Y. Du, “The roles of small-molecule inflammatory mediators in rheumatoid arthritis,” *Scandinavian Journal of Immunology*, vol. 93, no. 3, Article ID e12982, 2021.

[43] A. Hashimoto, I. Hayashi, Y. Murakami et al., “Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis,” *Journal of Rheumatology*, vol. 34, no. 11, pp. 2144–2153, 2007.

[44] S. Ramon, S. Bancos, C. N. Serhan, and R. P. Phipps, “Lipoxin A4 modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism,” *European Journal of Immunology*, vol. 44, no. 2, pp. 357–369, 2014.

[45] A. Zarbock, R. K. Polanowska-Gрабowska, and K. Ley, “Platelet-neutrophil-interactions: linking hemostasis and inflammation,” *Blood Reviews*, vol. 21, no. 2, pp. 99–111, 2007.

[46] A. A. Manfredi, M. Baldini, M. Camera et al., “Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 75, no. 8, pp. 1511–1520, 2016.

[47] J. Pancea, A. Ali, A. Ghaffar et al., “Upregulation of circulating inflammatory biomarkers under the influence of periodontal disease in rheumatoid arthritis patients,” *Cytokine*, vol. 131, Article ID 155117, 2020.

[48] Y. Tian, M. A. Terkawi, T. Onodera et al., “Blockade of XCL1/lymphotactin ameliorates severity of periarticular osteolysis triggered by polyethylene-particles,” *Frontiers in Immunology*, vol. 11, p. 1720, 2020.

[49] M. Endres, K. Andreas, G. Kalwitz et al., “Chemokine profile of synovial fluid from normal, osteoarthritis and rheumatoid arthritis patients: CCL25, CXCL10 and XCL1 recruit human subchondral mesenchymal progenitor cells,” *Osteoarthritis and Cartilage*, vol. 18, no. 11, pp. 1458–1466, 2010.

[50] J. Huang, X. Fu, X. Chen, L. Zheng, Y. Huang, and C. Liang, “Promising therapeutic targets for treatment of rheumatoid arthritis,” *Frontiers in Immunology*, vol. 12, Article ID 686155, 2021.
Evidence-Based Complementary and Alternative Medicine

[51] M. Yang, F. Wu, C. Xie et al., "Expression of CC chemokine ligand 5 in patients with rheumatoid arthritis and its correlation with disease activity and medication", Chinese Medical Sciences Journal, vol. 24, no. 1, pp. 50–54, 2009.

[52] Y. Miyabe, C. Miyabe, T. T. Murooka et al., "Complement C5a receptor is the key initiator of neutrophil adhesion igniting immune complex-induced arthritis", Science Immunology, vol. 2, no. 7, Article ID eaf2195, 2017.

[53] J.-H. Lee, B. Kim, W. J. Jin, H.-H Kim, H. Ha, and Z. H. Lee, "Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: relevance for arthritis", Arthritis Research & Therapy, vol. 19, no. 1, pp. 1–14, 2017.

[54] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-α is a negative regulator of macrophage activation”, Nature, vol. 391, no. 6662, pp. 79–82, 1998.

[55] C. Giaginis, A. Giagini, and S. Theocharis, "Peroxisome proliferator-activated receptor-γ ligands as potential therapeutic agents to treat arthritis", Pharmacological Research, vol. 60, no. 3, pp. 160–169, 2009.

[56] D. Xu, Y. Jiang, Y. Lu et al., "Long noncoding RNAs expression profile and functional networks in rheumatoid arthritis", Oncotarget, vol. 8, no. 56, Article ID 95280, 2017.

[57] L. Sun, J. Tu, C. Liu, A. Pan, X. Xia, and X. Chen, "Analysis of lncRNA expression profiles by sequencing reveals that Inc-l.l.928768.3 and Inc-AC091493.1 are novel biomarkers for disease risk and activity of rheumatoid arthritis", Inflammopharmacology, vol. 28, no. 2, pp. 437–450, 2020.

[58] D. R. Haynes, E. Barg, T. N. Crotti et al., "Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls", Rheumatology, vol. 42, no. 1, pp. 123–134, 2003.

[59] P. Geusens, "The role of RANK ligand/osteoprotegerin in rheumatoid arthritis", Therapeutic Advances in Musculoskeletal Disease, vol. 4, no. 4, pp. 225–232, 2012.

[60] S. Guo, L. Jia, T. Jiang et al., "(5R)-5-hydroxytriptolide (LLDT-8) induces substantial epigenetic mediated immune response network changes in fibroblast-like synoviocytes from rheumatoid arthritis patients", Scientific Reports, vol. 9, no. 1, 2019.

[61] C.-M. Yang, S.-F. Luo, H.-L. Hsieh et al., "Interleukin-1β induces ICAM-1 expression enhancing leukocyte adhesion in human rheumatoid arthritis synovial fibroblasts: involvement of ERK, JNK, AP-1, and NF-κB", Journal of Cellular Physiology, vol. 224, no. 2, pp. 516–526, 2010.

[62] S.-D. He, S.-C. Huang, H.-J. Zhu et al., "Oridonin suppresses autophagy and survival in rheumatoid arthritis fibroblast-like synoviocytes", Pharmaceutical Biology, vol. 58, no. 1, pp. 146–151, 2020.

[63] Z. Zhou, D. Xie, J. Huang et al., "Therapeutic effects of (5R)-5-hydroxytriptolide on fibroblast-like synoviocytes in rheumatoid arthritis via lncRNA WAKMAR2/miR-4478/ E2F1/p53 axis", Frontiers in Immunology, vol. 12, p. 296, 2021.

[64] P. Oelzner, S. Franke, G. Lehmann, T. Eidner, G. Hein, and G. Wolf, "The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis", Rheumatology International, vol. 32, no. 1, pp. 199–206, 2012.

[65] C. B. Little, A. Barai, D. Burkhardt et al., "Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development", Arthritis & Rheumatism, vol. 60, no. 12, pp. 3723–3733, 2009.

[66] L. J. Crofford, "Use of NSAIDs in treating patients with arthritis", Arthritis Research & Therapy, vol. 15, no. 3, 2013.

[67] Z. Tong, L. Cheng, J. Song et al., "Therapeutic effects of Caesalpinia minax Hance on complete Freund’s adjuvant (CFA)-induced arthritis and the anti-inflammatory activity of cascaine diterpenes as main active components", Journal of Ethnopharmacology, vol. 226, pp. 90–96, 2018.

[68] Y. He, Y. Yao, Q. Xie, X. Fang, and S. Liang, "Anti-rheumatoid arthritis potential of diterpenoid fraction derived from Rhododendron molle fruits", Chinese Journal of Natural Medicines, vol. 19, no. 3, pp. 181–187, 2021.

[69] Y. Shen, T. Jiang, R. Wang et al., "(5R)-5-hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway", BMC Complementary and Alternative Medicine, vol. 15, no. 1, pp. 1–10, 2015.

[70] Z. J. Zhai, H. W. Li, G. W. Liu et al., "Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo", British Journal of Pharmacology, vol. 171, no. 3, pp. 663–675, 2014.

[71] Y. Wang, S. Wang, Y. Li et al., "Therapeutic effect of cryptotanshinone on collagen-induced arthritis in rats via inhibiting nuclear factor kappa B signaling pathway", Translational Research, vol. 165, no. 6, pp. 704–716, 2015.

[72] B. Park, "Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells", Biochimie, vol. 105, pp. 129–136, 2014.

[73] H. Xu, H. Zhao, C. Lu et al., "Triptolide inhibits osteoclast differentiation and bone resorption in vitro via enhancing the production of IL-10 and TGF-β1 by regulatory T cells", Mediators of Inflammation, vol. 2016, Article ID 8048170, 10 pages, 2016.

[74] S.-W. Tsai, M.-C. Hsieh, S. Li et al., "Therapeutic potential of sclareol in experimental models of rheumatoid arthritis", International Journal of Molecular Sciences, vol. 19, no. 5, p. 1351, 2018.

[75] Y.-Y. Lin, Y.-H. Jean, H.-P. Lee et al., "Excavatolide B at therapeutic potential of rawalaria ligand 5 in patients with rheumatoid arthritis and its cor-
Evidence-Based Complementary and Alternative Medicine

[82] D. Fan, X. He, Y. Bian et al., “Triptolide modulates TREM-1 signal pathway to inhibit the inflammatory response in rheumatoid arthritis,” *International Journal of Molecular Sciences*, vol. 17, no. 4, p. 498, 2016.

[83] Y. Yang, Y. Ye, Q. Qiu et al., “Triptolide inhibits the migration and invasion of rheumatoid fibroblast-like synoviocytes by blocking the activation of the JNK MAPK pathway,” *International Immunopharmacology*, vol. 41, pp. 8–16, 2016.

[84] X. Zhang, X. Zhang, X. Wang et al., “Efficient delivery of triptolide plus a miR-30-5p inhibitor through the use of near infrared laser responsive or CADY modified MSNs for efficacy in rheumatoid arthritis therapeutics,” *Frontiers in Bioengineering and Biotechnology*, vol. 8, p. 170, 2020.

[85] L. Zhang, T. Wang, Q. Li et al., “Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo,” *International Journal of Nanomedicine*, vol. 11, p. 2663, 2016.

[86] M. Liu, J. Dong, Y. Yang, X. Yang, and H. Xu, “Anti-inflammatory effects of triptolide loaded poly (D,L-lactic acid) nanoparticles on adjuvant-induced arthritis in rats,” *Journal of Ethnopharmacology*, vol. 97, no. 2, pp. 219–225, 2005.

[87] J. Wu, Q. Li, L. Jin et al., “Kirenol inhibits the function and inflammation of fibroblast-like synoviocytes in rheumatoid arthritis in vitro and in vivo,” *Frontiers in Immunology*, vol. 10, p. 1304, 2019.

[88] C. Xie, J. Jiang, J. Liu, G. Yuan, and Z. Zhao, “Ginkgolide B attenuates collagen-induced rheumatoid arthritis and regulates fibroblast-like synoviocytes-mediated apoptosis and inflammation,” *Annals of Translational Medicine*, vol. 8, no. 22, 2020.

[89] Y.-Y. Lin, Y.-H. Jean, H.-P. Lee et al., “A soft coral-derived compound, 11-epi-sinularide acid suppresses inflammatory response and bone destruction in adjuvant-induced arthritis,” *PLoS One*, vol. 8, no. 5, Article ID e62926, 2013.

[90] Z. Cui, Y. Lin, Y. Liu, L. Cao, and L. Cui, “Retinoic acid-platinum (II) complex [RT-Pt (II)] protects against rheumatoid arthritis in mice via MEK/nuclear factor kappa B (NF-kB) pathway downregulation,” *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, vol. 26, Article ID e924787, 2020.

[91] J. Wu, X. Chen, L. Yuan et al., “Chinese herbal formula Huayu-Qiangshen-Tongbi decoction compared with leflunomide in combination with methotrexate in patients with active rheumatoid arthritis: an open-label, randomized, controlled, pilot study,” *Frontiers of Medicine*, vol. 7, p. 484, 2020.

[92] X. Zhang, Y. Dong, H. Dong, W. Zhang, and F. Li, “Investigation of the effect of phlomisoside F on complete Freund’s adjuvant-induced arthritis,” *Experimental and Therapeutic Medicine*, vol. 13, no. 2, pp. 710–716, 2017.

[93] F. Li, L. He, S. Luo et al., “Evaluation of the effect of andrographolide and methotrexate combined therapy in complete Freund’s adjuvant induced arthritis with reduced hepatotoxicity,” *Biomedicine & Pharmacotherapy*, vol. 106, pp. 637–645, 2018.

[94] S. Zhang, G. Huang, K. Yuan et al., “Tanshinone IIA ameliorates chronic arthritis in mice by modulating neutrophil activities,” *Clinical & Experimental Immunology*, vol. 190, no. 1, pp. 29–39, 2017.

[95] P. Olofsson, A. Nerstedt, M. Hultqvist et al., “Arthritis suppression by NADPH activation operates through an interferon-β pathway,” *BMC Biology*, vol. 5, no. 1, p. 19, 2007.

[96] J. Bert, M. L. Mahowald, S. Frizelle, C. W. Dorman, S. C. Funkenbusch, and H. E. Krug, “The effect of treatment with resinfloxacin and capsaicin on dynamic weight bearing measures and evoked pain responses in a chronic inflammatory arthritis murine model,” *Internal Medicine Review* (Washington, DC: Online), vol. 2016, no. 6, p. 89, 2016.

[97] R. N. Alolga, Y. Opoku-Damoah, D. A. Alagpulinsa et al., “Metabolomic and transcriptomic analyses of the anti-rheumatoid arthritis potential of xylopic acid in a bioinspired lipoprotein nanoformulation,” *Biomaterials*, vol. 268, Article ID 120482, 2021.

[98] Y. Wang, C. Zhou, H. Gao et al., “Therapeutic effect of cryptotanshinone on experimental rheumatoid arthritis through downregulating p300 mediated-STAT3 acetylation,” *Biochemical Pharmacology*, vol. 138, pp. 119–129, 2017.

[99] G. Xia, X. Wang, H. Sun, Y. Qin, and M. Fu, “Carnosic acid (CA) attenuates collagen-induced arthritis in db/db mice via inflammation suppression by regulating ROS-dependent p38 pathway,” *Free Radical Biology and Medicine*, vol. 108, pp. 418–432, 2017.

[100] A. E. Koch, S. L. Kunkel, L. A. Harlow et al., “Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis,” *The Journal of Clinical Investigation*, vol. 90, no. 3, pp. 772–779, 1992.

[101] S. I. Svetlov, J. M. Barton, and M. S. Olson, “The specific binding of the platelet-activating factor (PAF) receptor antagonist WEB 2086 and the benzoazepine flunitrazepam to rat hepatocytes,” *Life Sciences*, vol. 58, no. 5, pp. PL81–PL86, 1995.

[102] G.-J. Huang, C.-H. Pan, and C.-H. Wu, “Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model,” *Journal of Natural Products*, vol. 75, no. 1, pp. 54–59, 2012.

[103] P. Zhang, X. Shang, P. Tang et al., “Aphamines A–C, dimeric acyclic diterpene enantiomers from *Aphanamixis polyschachya*,” *Chinese Chemical Letters*, vol. 32, no. 4, pp. 1480–1484, 2021.

[104] M. Zhang, J. Wang, J. Luo, P. Wang, C. Guo, and L. Kong, “Labdane diterpenes from *Chloranthus serratus*,” *Fitoterapia*, vol. 91, pp. 95–99, 2013.

[105] J. Liu, Q. Wu, J. Shu, R. Zhang, and L. Liu, “Three new abietane-type diterpene glycosides from the roots of *Trip- terygium wilfordii*,” *Fitoterapia*, vol. 120, pp. 126–130, 2017.

[106] M. Tákei, A. Uemaya, and S. Arihara, “Diterpenes inhibit IL-12 production by DC and enhance Th2 cells polarization,” *Biochemical and Biophysical Research Communications*, vol. 355, no. 3, pp. 603–610, 2007.

[107] H. Khan, S. M. Nabavi, A. Sureda et al., “Therapeutic potential of songorine, a diterpenoid alkaloid of the genus Aconitum,” *Fitoterapia*, vol. 153, pp. 29–33, 2018.

[108] C. J. Malemud, “The role of the JAK/STAT signal pathway in rheumatoid arthritis,” *Therapeutic Advances in Musculoskeletal Disease*, vol. 10, no. 5-6, pp. 117–127, 2018.

[109] G. Giannelli, R. Erriquez, F. Iannone, F. Marinosci, G. Lapadula, and S. Antonaci, “MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis,” *Clinical & Experimental Rheumatology*, vol. 22, no. 3, pp. 335–338, 2004.

[110] Y. Zhong, Y. Huang, M. B. Santoso, and L.-D. Wu, “Sclareol exerts anti-osteoarthritic activities in interleukin-1β-induced rabbit chondrocytes and a rabbit osteoarthritis model,” *Osteoarthritis and Cartilage*, vol. 19, no. 9, pp. 1005–1012, 2011.
International Journal of Clinical and Experimental Pathology, vol. 8, no. 3, p. 2365, 2015.

[111] Y. Tanaka, T. Takeuchi, H. Yamanaka et al., “A phase 2 study of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs,” Modern Rheumatology, vol. 31, no. 4, pp. 783–789, 2021.

[112] J. Schwager, N. Richard, A. Fowler, N. Seifert, and D. Raederstorff, “Carnosol and related substances modulate chemokine and cytokine production in macrophages and chondrocytes,” Molecules, vol. 21, no. 4, p. 465, 2016.

[113] R. Zhou, W. Tang, Y.-X. Ren et al., “(5R)-5-hydroxytriptolide attenuated collagen-induced arthritis in DBA/1 mice via suppressing interferon-γ production and its related signaling,” Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 1, pp. 35–44, 2006.

[114] J.-Z. Zeng, L.-F. Ma, H. Meng, H.-M. Yu, Y.-K. Zhang, and A. Guo, “(5R)-5-hydroxytriptolide (LLDT-8) prevents collagen-induced arthritis through OPG/RANK/RANKL signaling in a rat model of rheumatoid arthritis,” Experimental and Therapeutic Medicine, vol. 12, no. 5, pp. 3101–3106, 2016.

[115] G. Li, Y. Liu, F. Meng et al., “LncRNA MEG3 inhibits rheumatoid arthritis through miR-141 and inactivation of AKT/mTOR signalling pathway,” Journal of Cellular and Molecular Medicine, vol. 23, no. 10, pp. 7116–7120, 2019.

[116] X. Lv, S. Chen, J. Li, J. Fang, Y. Guo, and K. Ding, “lobolide, a diterpene, blockades the NF-κB pathway and p38 and ERK MAPK activity in macrophages in vitro,” Acta Pharmacologica Sinica, vol. 33, no. 10, pp. 1293–1300, 2012.

[117] S. Y. Wong, M. G. K. T. Tan, W. A. Banks, W. S. F. Wong, P. T.-H. Wong, and M. K. P. Lai, “Andrographolide attenuates LPS-stimulated up-regulation of CC and CXC motif chemokines in rodent cortex and primary astrocytes,” Journal of Neuroinflammation, vol. 13, no. 1, p. 34, 2016.

[118] J.-J. Chen, C.-W. Ting, Yi-C. Wu et al., “New labdane-type diterpenoids and anti-inflammatory constituents from Hedychium coronarium,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 13063–13077, 2013.

[119] M. A. Callender and E. S. Antonarakis, “Rheumatoid arthritis masked by docetaxel chemotherapy in a patient with ovarian carcinoma,” Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, vol. 14, no. 2, p. 121, 2008.

[120] V. Lanzotti, “Diterpenes for therapeutic use,” in Natural Products, pp. 3173–3191, Springer, Berlin, Germany, 2013.